Zytiga's use expanded for advanced prostate cancer

Zytiga's Use Expanded for Advanced Prostate Cancer
Zytiga's Use Expanded for Advanced Prostate Cancer

(HealthDay News) -- U.S. Food and Drug Administration approval of Zytiga (abiraterone acetate) has been expanded to include treating late-stage castration-resistant prostate cancer before the administration of chemotherapy, the agency said today.

The drug, designed to decrease production of testosterone, was first approved in November 2011 for use in patients whose prostate cancer progressed after treatment with docetaxel.

Zytiga's approval for the new use followed a clinical study of 1,088 men with advanced, castration-resistant prostate cancer who hadn't received chemotherapy. Men who took Zytiga had a median survival of 35.3 months, compared to 30.1 months among those who took a placebo.

The most common adverse reactions included fatigue, swollen joints, hot flushes, diarrhea, vomiting, cough, and high blood pressure.

Zytiga is marketed by Janssen Biotech, based in Horsham, Pa.

More Information

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs